163 related articles for article (PubMed ID: 33035473)
1. Risk of cervical precancer and cancer among uninsured and underserved women from 2009 to 2017.
Saraiya M; Cheung LC; Soman A; Mix J; Kenney K; Chen X; Perkins RB; Schiffman M; Wentzensen N; Miller J
Am J Obstet Gynecol; 2021 Apr; 224(4):366.e1-366.e32. PubMed ID: 33035473
[TBL] [Abstract][Full Text] [Related]
2. Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting.
Landy R; Schiffman M; Sasieni PD; Cheung LC; Katki HA; Rydzak G; Wentzensen N; Poitras NE; Lorey T; Kinney WK; Castle PE
Int J Cancer; 2020 Feb; 146(3):617-626. PubMed ID: 30861114
[TBL] [Abstract][Full Text] [Related]
3. The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.
Silver MI; Schiffman M; Fetterman B; Poitras NE; Gage JC; Wentzensen N; Lorey T; Kinney WK; Castle PE
Cancer; 2016 Dec; 122(23):3682-3686. PubMed ID: 27657992
[TBL] [Abstract][Full Text] [Related]
4. [Real-world research on cervical cancer screening program and effect evaluation for Chinese population].
Zhao YQ; Dai Y; Dang L; Kong LH; Zhang Y; Feng RM; Qiao YL; Lang JH
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):764-771. PubMed ID: 30392341
[No Abstract] [Full Text] [Related]
5. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
[TBL] [Abstract][Full Text] [Related]
6. Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer.
Clarke MA; Fetterman B; Cheung LC; Wentzensen N; Gage JC; Katki HA; Befano B; Demarco M; Schussler J; Kinney WK; Raine-Bennett TR; Lorey TS; Poitras NE; Castle PE; Schiffman M
J Clin Oncol; 2018 Apr; 36(12):1184-1191. PubMed ID: 29356609
[TBL] [Abstract][Full Text] [Related]
7. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
8. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
Clarke MA; Cheung LC; Castle PE; Schiffman M; Tokugawa D; Poitras N; Lorey T; Kinney W; Wentzensen N
JAMA Oncol; 2019 Feb; 5(2):181-186. PubMed ID: 30325982
[TBL] [Abstract][Full Text] [Related]
9. Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results.
Castle PE; Kinney WK; Xue X; Cheung LC; Gage JC; Poitras NE; Lorey TS; Katki HA; Wentzensen N; Schiffman M
J Natl Cancer Inst; 2019 Aug; 111(8):820-827. PubMed ID: 30576462
[TBL] [Abstract][Full Text] [Related]
10. Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results.
Castle PE; Xie X; Xue X; Poitras NE; Lorey TS; Kinney WK; Wentzensen N; Strickler HD; Burger EA; Schiffman M
Prev Med; 2019 Jan; 118():44-50. PubMed ID: 30316878
[TBL] [Abstract][Full Text] [Related]
11. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
12. Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.
Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LC; Cuzick J; Myers O; Castle PE; Wheeler CM;
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):36-42. PubMed ID: 26518316
[TBL] [Abstract][Full Text] [Related]
13. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB
Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
[TBL] [Abstract][Full Text] [Related]
14. Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta-analysis.
Malagón T; Volesky KD; Bouten S; Laprise C; El-Zein M; Franco EL
Int J Cancer; 2020 Nov; 147(10):2695-2707. PubMed ID: 32363604
[TBL] [Abstract][Full Text] [Related]
15. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.
Safaeian M; Solomon D; Wacholder S; Schiffman M; Castle P
Obstet Gynecol; 2007 Jun; 109(6):1325-31. PubMed ID: 17540804
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus vaccination history and diagnosis of cervical intraepithelial neoplasia grade ≥2 severe lesions among a cohort of women who underwent colposcopy in Kaiser Permanente Southern California.
Lonky NM; Xu L; Da Silva DM; Felix JC; Chao C
Am J Obstet Gynecol; 2021 Dec; 225(6):656.e1-656.e11. PubMed ID: 34273278
[TBL] [Abstract][Full Text] [Related]
17. A prospective study of risk-based colposcopy demonstrates improved detection of cervical precancers.
Wentzensen N; Walker J; Smith K; Gold MA; Zuna R; Massad LS; Liu A; Silver MI; Dunn ST; Schiffman M
Am J Obstet Gynecol; 2018 Jun; 218(6):604.e1-604.e8. PubMed ID: 29462629
[TBL] [Abstract][Full Text] [Related]
18. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014-2016.
Ouh YT; Min KJ; Cho HW; Ki M; Oh JK; Shin SY; Hong JH; Lee JK
J Gynecol Oncol; 2018 Jan; 29(1):e14. PubMed ID: 29185272
[TBL] [Abstract][Full Text] [Related]
20. Risk of cervical precancer and cancer in women aged 30 years and older with an HPV-negative low-grade squamous intraepithelial lesion screening result.
Littell RD; Kinney W; Fetterman B; Cox JT; Shaber R; Poitras N; Lorey T; Castle PE
J Low Genit Tract Dis; 2011 Jan; 15(1):54-9. PubMed ID: 21192178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
